These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25891945)

  • 1. The integration of solid-form informatics into solid-form selection.
    Feeder N; Pidcock E; Reilly AM; Sadiq G; Doherty CL; Back KR; Meenan P; Docherty R
    J Pharm Pharmacol; 2015 Jun; 67(6):857-68. PubMed ID: 25891945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight to the thermodynamic stability of molecular crystals through crystallographic studies of a multipolymorph system.
    Ng AT; Lai C; Dabros M; Gao Q
    J Pharm Sci; 2014 Nov; 103(11):3423-3431. PubMed ID: 25252084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal polymorphism in chemical process development.
    Lee AY; Erdemir D; Myerson AS
    Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
    Erdemir D; Lee AY; Myerson AS
    Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The computational prediction of pharmaceutical crystal structures and polymorphism.
    Price SL
    Adv Drug Deliv Rev; 2004 Feb; 56(3):301-19. PubMed ID: 14962583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico identification of bioisosteric functional groups.
    Ertl P
    Curr Opin Drug Discov Devel; 2007 May; 10(3):281-8. PubMed ID: 17554854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
    Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
    Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD; Marziano I
    J Pharm Pharmacol; 2015 Jun; 67(6):782-802. PubMed ID: 25677227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polymorph transformation of solid drugs].
    Zhang Q; Mei XF
    Yao Xue Xue Bao; 2015 May; 50(5):521-7. PubMed ID: 26234130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amide-N-oxide heterosynthon and amide dimer homosynthon in cocrystals of carboxamide drugs and pyridine N-oxides.
    Babu NJ; Reddy LS; Nangia A
    Mol Pharm; 2007; 4(3):417-34. PubMed ID: 17497888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent hydrogen bonding in polymorphic crystal structures.
    Galek PT; Fábián L; Allen FH
    Acta Crystallogr B; 2009 Feb; 65(Pt 1):68-85. PubMed ID: 19155561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Crystal Structure Informatics for Defining the Conformational Space Needed for Predicting Crystal Structures of Pharmaceutical Molecules.
    Iuzzolino L; Reilly AM; McCabe P; Price SL
    J Chem Theory Comput; 2017 Oct; 13(10):5163-5171. PubMed ID: 28892623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hierarchy of supramolecular synthons: persistent hydroxyl...pyridine hydrogen bonds in cocrystals that contain a cyano acceptor.
    Bis JA; Vishweshwar P; Weyna D; Zaworotko MJ
    Mol Pharm; 2007; 4(3):401-16. PubMed ID: 17500564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the structural motifs and packing arrangements of six novel derivatives and one polymorph of 2-(1-phenyl-1H-1,2,3-triazol-4-yl)pyridine.
    Tawfiq KM; Miller GJ; Al-Jeboori MJ; Fennell PS; Coles SJ; Tizzard GJ; Wilson C; Potgieter H
    Acta Crystallogr B Struct Sci Cryst Eng Mater; 2014 Apr; 70(Pt 2):379-89. PubMed ID: 24675607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid-state properties and crystallization behavior of PHA-739521 polymorphs.
    Sun CC
    Int J Pharm; 2006 Aug; 319(1-2):114-20. PubMed ID: 16720086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving polymorph selectivity in the crystallization of pharmaceutical solids: basic considerations and recent advances.
    Reutzel-Edens SM
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):806-15. PubMed ID: 17117688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of known crystals to design polymorph prediction strategies.
    Young PH; Ando HY
    J Pharm Sci; 2007 May; 96(5):1203-36. PubMed ID: 17455343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.